Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced the appointment of Dr. Jeremy R. Graff as President and Chief Development Officer effective September 30, 2024. Dr. Graff, with over 25 years of experience in the biotech and pharmaceutical industry, has held various C-level and senior executive positions and has a strong background in the development of targeted cancer therapies. Prior to joining Allarity, he served as a consultant to the company and held roles at IMV, Inc., HiberCell, and Biothera Pharmaceuticals, Inc. He also worked at Eli Lilly for nearly 17 years. Dr. Graff's appointment is part of a strategic move to strengthen the company's leadership as it advances its clinical development programs, particularly the stenoparib PARP inhibitor program. Alongside Dr. Graff's appointment, Allarity has also brought on Dr. Jose Iglesias as Consultant Chief Medical Officer and Jesper Høiland as Strategic Advisor. The company is focused on the development of stenoparib using its Drug Response Predictor (DRP®) companion diagnostic for patient selection in ongoing clinical trials.

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced the appointment of Dr. Jeremy R. Graff as President and Chief Development Officer effective September 30, 2024. Dr. Graff, with over 25 years of experience in the biotech and pharmaceutical industry, has held various C-level and senior executive positions and has a strong background in the development of targeted cancer therapies. Prior to joining Allarity, he served as a consultant to the company and held roles at IMV, Inc., HiberCell, and Biothera Pharmaceuticals, Inc. He also worked at Eli Lilly for nearly 17 years. Dr. Graff's appointment is part of a strategic move to strengthen the company's leadership as it advances its clinical development programs, particularly the stenoparib PARP inhibitor program. Alongside Dr. Graff's appointment, Allarity has also brought on Dr. Jose Iglesias as Consultant Chief Medical Officer and Jesper Høiland as Strategic Advisor. The company is focused on the development of stenoparib using its Drug Response Predictor (DRP®) companion diagnostic for patient selection in ongoing clinical trials.